Vivo Opportunity, LLC - Apr 1, 2024 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
10%+ Owner
Signature
/s/ Kevin Dai, as a managing member of Vivo Opportunity, LLC
Stock symbol
TERN
Transactions as of
Apr 1, 2024
Transactions value $
-$2,796,859
Form type
4
Date filed
4/3/2024, 08:47 PM
Previous filing
Oct 4, 2023
Next filing
May 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TERN Common Stock Sale -$952K -136K -3.14% $6.99 4.2M Apr 1, 2024 By Vivo Opportunity Fund Holdings, L.P. F1, F4, F5
transaction TERN Common Stock Sale -$275K -39.4K -1.94% $6.99 2M Apr 1, 2024 By: Vivo Capital Fund VIII, L.P. F2, F4, F5
transaction TERN Common Stock Sale -$38.1K -5.45K -1.94% $6.99 276K Apr 1, 2024 By: Vivo Capital Surplus Fund VIII, L.P. F3, F4, F5
transaction TERN Common Stock Sale -$508K -76.3K -1.82% $6.65 4.13M Apr 2, 2024 By Vivo Opportunity Fund Holdings, L.P. F1, F4, F6
transaction TERN Common Stock Sale -$147K -22.1K -1.11% $6.65 1.98M Apr 2, 2024 By: Vivo Capital Fund VIII, L.P. F2, F4, F6
transaction TERN Common Stock Sale -$20.3K -3.05K -1.11% $6.65 273K Apr 2, 2024 By: Vivo Capital Surplus Fund VIII, L.P. F3, F4, F6
transaction TERN Common Stock Sale -$644K -104K -2.52% $6.20 4.02M Apr 3, 2024 By Vivo Opportunity Fund Holdings, L.P. F1, F4, F7
transaction TERN Common Stock Sale -$186K -30K -1.52% $6.20 1.95M Apr 3, 2024 By: Vivo Capital Fund VIII, L.P. F2, F4, F7
transaction TERN Common Stock Sale -$25.7K -4.15K -1.52% $6.20 269K Apr 3, 2024 By: Vivo Capital Surplus Fund VIII, L.P. F3, F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vivo Opportunity, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2 The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3 The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F4 The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023.
F5 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
F6 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
F7 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4.